Tbilisi held a Scientific Conference “Cancer Immunotherapy – New Paradigm in Cancer Treatment”. The conference was organized by Roche Georgia and connected to the introduction of the innovative immunotherapy drug onto the Georgian pharmaceutical market.
Special Speaker Professor Lasar Popovich, MD, PhD, from Medical Oncology Department, Oncology Institute of Vojvodina, Serbia, was invited to participate in the conference. The conference was attended by representatives of the Health Care System and media.
The new drug is the first approved anti-PD-L1 agent in Cancer Immunotherapy designed to target and bind to a protein called PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells and may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells. Drug is approved for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) and locally advanced or metastatic bladder cancer.
“Roche is the global leader in Oncology and pioneer in development of Personalized Health Care (PHC). The aim of PHC is to provide right treatment to right patient at right time. The new cancer immunotherapy drug is the part of PHC” – comments Nino Ganugrava, Medical Director of Roche Georgia. According to her in the past decade cancer therapy has seen revolutionary research advances. But until recently Bladder Cancer had not seen any major advances for more than 30 years. “We are delighted that Roche’s immunotherapy drug was approved in both advanced bladder and advanced lung cancer. We believe that with this innovative treatment, patients will live longer and better”